Apo(a) Antikörper

Produktnummer ABIN113082

Der Schaf Polyklonal anti-Apo(a) Antikörper (ABIN113082) detektiert spezifisch Apo(a) in WB und EIA. Dieser Antikörper reagiert spezifisch mit Proben aus Säugetier.

Kurzübersicht für Apo(a) Antikörper (ABIN113082)

Target: Apo(a) (apo(a)) (Apolipoprotein A (apo(a)))

Reaktivität: Säugetier

Wirt: Schaf

Klonalität: Polyklonal

Konjugat: Dieser Apo(a) Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Enzyme Immunoassay (EIA)

Produktdetails anti-Apo(a) Antikörper

Spezifität: Specifically binds to human Lp(a) and apo(a). No cross-reaction to Apo B-100/48, minor to plasminogen.

Aufreinigung: Human Apo (a) Sepharose affinity column. Cross-reactivity to plasminogen was removed by passing plasminogen Sepharose affinity column.

Anwendungsinformationen

Applikationshinweise: Suitable for use in ELISA (1: 7,500-1: 60,000), Western blot and conjugation purposes.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1,0 mg/mL (OD280nm, E0.1% = 1.35)

Buffer: 75 mM PBS, 75 m mM Sodium chloride, pH 7.2 containing 0.02 % Sodium azide as preservative.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Avoid repeated freezing and thawing.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.

Details zu Apo(a)

Target: Apo(a) (apo(a)) (Apolipoprotein A (apo(a)))

Andere Bezeichnung: Apolipoprotein(a) / LP(a)

Hintergrund: Lipoprotein(a) (Lp(a)) is a lipoprotein subclass assembled in the blood from low density lipoprotein (LDL) molecules and apolipoprotein-a (apo-a). Lp(a) recruits inflammatory cells through interaction with Mac-1 integrin. High Lp(a) in blood is a risk factor for coronary heart disease, cerebrovascular disease, atherosclerosis, thrombosis, and stroke. Lp(a) concentrations may be affected by disease states, but are only moderately affected by diet, exercise and other environmental factors. Lipid-reducing drugs have no effect on Lp(a) concentration. High Lp(a) predicts risk of early atherosclerosis similar to high LDL, but in advanced atherosclerosis, Lp(a) is a risk factor independent of LDL, indicating a coagulant risk of plaque thrombosis. Apo(a) contains domains that are very similar to plasminogen (PLG). Lp(a) accumulates in the vessel wall and inhibits binding of PLG to the cell surface, reducing plasmin generation which increases clotting. This inhibition also promotes proliferation of smooth muscle cells. These unique features of Lp(a) suggest a role in the generation of clots and atherosclerosis.Synonyms: Apo(a), LPA

Gen-ID: 4018

NCBI Accession: NP_005568

UniProt: P08519